source
- Argenx to acquire Unnatural Products' macrocyclic peptide platform for $550 million upfrontArgenx announced that it will acquire the California-based protein specialist Unnatural Products, paying $550 million upfront for its macrocyclic peptide platform. The deal could rise to more than…
- Delix Therapeutics raises $100M Series C to advance non-hallucinatory psychedelic for depressionDelix Therapeutics announced a $100 million Series C financing round, led by Johnson & Johnson’s venture arm JJDC and joined by investors such as SV Health Investors’ Dementia Discovery Fund, RA Ca…